Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Study: Heart Attack Outcomes Far Worse for Those With COVID-19

New research from the Smidt Heart Institute at Cedars-Sinai shows that patients who went to a hospital with a heart attack and were simultaneously sick with COVID-19 were three times more likely to die than patients experiencing a heart attack without a COVID-19 infection.

The study published in the peer-reviewed journal Current Problems in Cardiology-also found that the Black, Hispanic, Asian, and Pacific Islander patients who had both COVID-19 and acute myocardial infarction (AMI)-the medical term for a heart attack-fared worse than their white counterparts.

“The COVID-19 pandemic had a significant impact on heart attack patients and disrupted optimal care that led to delays and changes in traditional, often lifesaving treatment approaches,” said Martha Gulati, MD, director of Preventive Cardiology in the Smidt Heart Institute and the study’s senior author. “Most importantly, we found significant racial disparities in the management of AMI in patients with concurrent COVID-19, with Black, Hispanic, Asian, and Pacific Islander patients receiving lower rates of treatment when compared to white patients.”

Gulati, the Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine and Research and the associate director of the Barbra Streisand Women’s Heart Center, said these findings point to the urgent need to address disparities and enhance access to care.

As investigators explain, the COVID-19 pandemic put a spotlight on gaps in cardiovascular care that already existed based on race and ethnicity. Addressing these disparities in healthcare urgently requires a multifaceted approach.

“While this study provides valuable insight, it is one piece of the puzzle,” said Christine M. Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute. “Addressing healthcare disparities, particularly during a global pandemic, requires a concerted effort from all stakeholders, including policymakers, healthcare providers, and the community at large.”

The Cedars-Sinai Newsroom sat down with Gulati to learn how the findings of this research study prompted ideas on addressing healthcare disparities and enhancing access to care:

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy